Kirkland & Ellis LLP advised GTCR LLC, a leading private equity firm, on its acquisition of Albany Molecular Research, Inc. (NASDAQ:AMRI) (‘AMRI’), a global contract research, development and manufacturing organization, alongside the Carlyle Group, a global alternative asset manager. Under the terms of the agreement AMRI’s stockholders will receive $21.75 per share in cash, representing a 42 percent premium over the 60-day weighted average closing stock price. Closing of the transaction is subject to customary conditions. The full press release is available here. The Kirkland team was led by corporate partners Sanford Perl, Michael Weed, William Sorabella, Daniel Guerin and Christopher Butler.